April 2022

Acute graft-versus-host disease (aGVHD) is the most frequently encountered, life- threatening complication following an allogeneic hematopoietic stem cell transplant (aHSCT).

Two-thirds of women diagnosed with endometrial cancer have localized disease and a 5-year relative survival of 95%.

An expert panel engaged the audience in a live virtual symposium and case discussion on immune checkpoint inhibitors (ICIs) in the first-line treatment of non−small cell lung cancer (NSCLC) at the 2021 ASHP Midyear Clinical Meeting.

Attendees of this live virtual program learned the latest and greatest in a presentation from 2 expert oncology pharmacists.

In a live virtual symposium at the 2021 ASHP Midyear Clinical Meeting, 2 experts teamed up to highlight the place in therapy and management of oral oncolytics in follicular and marginal zone lymphoma.

The agent is the first oral therapy for this indication.

Asciminib offers a new option for patients harboring the T315I mutation.

The oral PARP inhibitor is associated with increased PFS, regardless of BRCA mutational status.

New therapies and combination regimens may allow a more tailored approach.

Numbers have remained below prepandemic levels.

Biosimilars could save consumers more than $100 billion in the coming years.

Cutaneous squamous cell carcinoma should be diagnosed early and treated promptly to avoid complications.

A variety of strategies can help increase patient adherence to oral chemotherapy.

Oncology and specialty treatments advance alongside care.

We see today far more clearly the impact of health care inequality, which can directly affect patient access to care, specifically oncologic care.